Too much HER2 protein, however, can cause some types of breast cancer to grow and spread. HER2-positive breast cancers have ...

Thanks to these treatments, five-year survival rates for people with HER2-positive metastatic breast cancer who are hormone-receptor positive are slightly higher than those who are negative. The goal ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared ... the overall 5-year relative survival rate for breast cancer is 91.2%. If the tumor is still ...

The biggest increase in 2-year survival associated with Medicaid expansion was among patients with stage III disease, with a ...

Dispelling myths around breast cancer in Africa is important so that treatment care can focus on the dire socio-economic ...

Medicaid expansion improved 2-year survival rates and access to guideline-concordant treatment for patients with HR-negative and HER2-positive breast cancer. The study highlights the role of ...

Inavolisib is approved for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer, showing improved progression-free survival and objective response rate. The phase 3 ...

Expanding Medicaid is associated with an increase in receipt of guideline-concordant treatment among nonelderly women ...

"Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer, Journal of the ...

Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...